To the Editor: Introduction Elevated transaminases are a common complication of many drugs, occurring in up to 27% of patients taking atypical antipsychotics medications (Atasoy et al. 2007). For patients who have no other options than remaining on certain antipsychotics such as olanzapine, physicians must weigh the risks versus benefits of continuing antipsychotic medications. We present a case study that attempted to replicate a previous single case study in which vitamin E therapy successfully reduced damaging effects of olanzapine on liver enzymes (Do¨nmez et al. 2017).